GlassScriptPhysician profile
Nimrod Lavi
NPI 1477641264
$6,042.02
in general payments reported to CMS, 2019-2025
13 companies · $2,474 in 2025
The $2,474 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,030 · 2020: $14.65 · 2021: $13.33 · 2022: $18.35 · 2023: $28.37 · 2024: $2,463 · 2025: $2,474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $4,000 · Food and Beverage: $966.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $4,000.00 |
| Food and Beverage | $965.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $4,019.21 | 2024-2025 | Lifevest |
| Medtronic Vascular, INC. | $803.36 | 2019 | |
| Biosense Webster, INC. | $624.82 | 2024-2025 | Carto 3 |
| E.R. Squibb & Sons, L.L.C. | $141.44 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $126.29 | 2019-2024 | |
| Medtronic, INC. | $74.21 | 2025 | |
| Novo Nordisk INC | $67.48 | 2024 | Wegovy |
| Amgen INC. | $58.52 | 2019 | |
| Glaxosmithkline, LLC. | $53.98 | 2025 | Arexvy, Shingrix, Fluarix Quadrivalent |
| Bayer Healthcare Pharmaceuticals INC. | $21.53 | 2025 | |
| Impulse Dynamics (USA) INC. | $18.35 | 2022 | |
| Janssen Pharmaceuticals, INC | $18.18 | 2019 | |
| Pfizer INC. | $14.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nimrod Lavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.